Molecular approaches to the development of drugs for AIT: peculiarities of the immune tolerance induction
AbstractMore than 30 % of the world’s inhabitants suffer from allergies. Allergen-specific immunotherapy (AIT) is considered to be the only pathogenetic method of allergy treatment that can provide a long-term effect. This method involves regular administration of therapeutic allergens or allergy vaccines to reduce the severity of clinical manifestations of allergy by inducing immune tolerance to the target allergen. However, AIT has disadvantages: low quality of preparations of therapeutic antigens and allergy vaccines based on them, the risk of side effects, and the duration of the course of treatment. For more than a century of AIT use, significant progress has been made in the development of new immunotherapy technologies and in the study of allergy mechanisms. The molecular approach to the development of allergy vaccines is becoming increasingly popular. It makes it possible to improve their safety, efficacy and standardize the production process. In this review, the main stages of AIT development and various technologies for the development of therapeutic allergen preparations and allergy vaccines are discussed. Special attention is paid to modern molecular methods of immunotherapy. Current understanding of the pathogenesis of allergy and mechanisms of AIT are also summarized.
Keywords:immunologic tolerance; allergen-specific immunotherapy (AIT); allergy vaccines
For citation: Pasikhov G.B., Shilovskiy I.P., Kurbacheva O.M., Vinogradova K.V., Popova M.V., Strueva P.A., Tahanovich A.D., Kadushkin A.G., Gudima G.O., Kudlay D.A., Khaitov M.R. Molecular approaches to the development of drugs for AIT: peculiarities of the immune tolerance induction. Immunologiya. 2024; 45 (3): 367–84. DOI: https://doi.org/10.33029/1816-2134-2024-45-3-367-384 (in Russian)
Funding. The study was supported by Russian Science Foundation grant No. 23-45-10031 (https://rscf.ru/project/23-45-10031/).
Conflict of interests. The authors declare no conflict of interests.
Authors’ contribution. All authors have contributed equally to the study, read the final version of the article and agreed with its contents.
References
1. Mazur M., Czarnobilska M., Dyga W., Czarnobilska E. Trends in the Epidemiology of Allergic Diseases of the Airways in Children Growing Up in an Urban Agglomeration. J Clin Med. 2022; 11 (8): 2188. DOI: https://doi.org/10.3390/jcm11082188
2. Seité S., Taieb C., Lazic Strugar T., Lio P., Bobrova E.E. Self-reported allergies in Russia and impact on skin. SAGE Open Med. 2020; 8: 2050312120957916. DOI: https://doi.org/10.1177/2050312120957916
3. Dorofeeva Y., Shilovskiy I., Tulaeva I., Focke-Tejkl M., Flicker S., Kudlay D., Khaitov M., Karsonova A., Riabova K., Karaulov A., Khanferyan R., Pickl W.F., Wekerle T., Valenta R. Past, present, and future of allergen immunotherapy vaccines. Allergy. 2021; 76 (1): 131–49. DOI: https://doi.org/10.1111/all.14300
4. Bush A. Pathophysiological Mechanisms of Asthma. Front Pediatr. 2019; 7: 68. DOI: https://doi.org/10.3389/fped.2019.00068
5. Shilovskiy I.P., Nikolskii A.A., Kurbacheva O.M., Khaitov M.R. Modern View of Neutrophilic Asthma Molecular Mechanisms and Therapy. Biochemistry (Mosc). 2020; 85 (8): 854–68. DOI: https://doi.org/10.1134/S0006297920080027
6. Khaitov M.R., Gaisina A.R., Shilovskiy I.P., Smirnov V.V., Ramenskaia G.V., Nikonova A.A., Khaitov R.M. The Role of Interleukin-33 in Pathogenesis of Bronchial Asthma. New Experimental Data. Biochemistry (Moscow). 2018; 83 (1): 13–25. DOI: https://doi.org/10.1134/S0006297918010029
7. Shilovskiy I.P., Eroshkina D.V., Babakhin A.A., Khaitov M.R. Anticytokine therapy of allergic asthm]. Mol Biol (Mosk). 2017; 51(1): 3-17. DOI: https://doi.org/10.7868/S0026898416060197 (in Russian)
8. Shilovskiy I.P., Kovchina V.I., Timotievich E.D., Nikolskii A.A., Khaitov M.R. Role and Molecular Mechanisms of Alternative Splicing of Th2-Cytokines IL-4 and IL-5 in Atopic Bronchial Asthma. Biochemistry (Mosc). 2023; 88 (10): 1608–21. DOI: https://doi.org/10.1134/S0006297923100152
9. Curin M., Khaitov M., Karaulov A., Namazova-Baranova L., Campana R., Garib V., Valenta R. Next-Generation of Allergen-Specific Immunotherapies: Molecular Approaches. Curr Allergy Asthma Rep. 2018; 18 (7): 39. DOI: https://doi.org/10.1007/s11882-018-0790-x
10. Pavlova K.S., Timoshenko D.O., Gushchin I.S., Kurbacheva O.M. Allergen immunotherapy: on the path to achieving immune tolerance. Immunologiya. 2024; 45 (1): 82–90. DOI: https://doi.org/10.33029/1816-2134-2024-45-1-82-90 (in Russian)
11. Kurbacheva O.M., Pavlova K.S., Kozulina I.E. Allergen-specific immunotherapy: history, methods and new options. Meditsinskiy sovet [Medical Council]. 2013; (3-2): 10–9. DOI: https://doi.org/10.21518/2079-701X-2013-3-2-10-19 (in Russian)
12. Kucuksezer U.C., Ozdemir C., Cevhertas L., Ogulur I., Akdis M., Akdis C.A. Mechanisms of allergen-specific immunotherapy and allergen tolerance. Allergol Int. 2020; 69 (4): 549–60. DOI: https://doi.org/10.1016/j.alit.2020.08.002
13. López J.F., Bel Imam M., Satitsuksanoa P., Lems S., Yang M., Hwang Y.K., Losol P., Choi J.P., Kim S.H., Chang Y.S., Akdis M., Akdis C.A., van de Veen W. Mechanisms and biomarkers of successful allergen-specific immunotherapy. Asia Pac Allergy. 2022; 12 (4): e45. DOI: https://doi.org/10.5415/apallergy.2022.12.e45
14. Feng M., Su Q., Lai X., Xian M., Shi X., Wurtzen P.A., Qin R., Zeng X., Li J. Functional and Immunoreactive Levels of IgG4 Correlate with Clinical Responses during the Maintenance Phase of House Dust Mite Immunotherapy. J Immunol. 2018; 200 (12): 3897–904. DOI: https://doi.org/10.4049/jimmunol.1701690
15. Zhernov Y., Curin M., Khaitov M., Karaulov A., Valenta R. Recombinant allergens for immunotherapy: state of the art. Curr Opin Allergy Clin Immunol. 2019; 19 (4): 402–14. DOI: https://doi.org/10.1097/ACI.0000000000000536
16. Frew A.J., Pfaar O. Placebo effects in allergen immunotherapy: an experts’ opinion. Allergo J Int. 2018; 27 (6): 162–6. DOI: https://doi.org/10.1007/s40629-018-0065-z
17. Kiel M.A., Röder E., Gerth van Wijk R., Al M.J., Hop W.C., Rutten-van Mölken M.P. Real-life compliance and persistence among users of subcutaneous and sublingual allergen immunotherapy. J Allergy Clin Immunol. 2013; 132 (2): 353–60.e2. DOI: https://doi.org/10.1016/j.jaci.2013.03.013
18. Valenta R., Karaulov A., Niederberger V., Zhernov Y., Elisyutina O., Campana R., Focke-Tejkl M., Curin M., Namazova-Baranova L., Wang J.Y., Pawankar R., Khaitov M. Allergen Extracts for In Vivo Diagnosis and Treatment of Allergy: Is There a Future? J Allergy Clin Immunol Pract. 2018; 6 (6): 1845–55.e2. DOI: https://doi.org/10.1016/j.jaip.2018.08.032
19. Chu D.K., Wood R.A., French S., Fiocchi A., Jordana M., Waserman S., Brożek J.L., Schünemann H.J. Oral immunotherapy for peanut allergy (PACE): a systematic review and meta-analysis of efficacy and safety. Lancet. 2019; 393 (10187): 2222–32. DOI: https://doi.org/10.1016/S0140-6736(19)30420-9
20. Crameri R., Graf N., Johansen P., Kündig T.M. Intralymphatic allergen administration renders specific immunotherapy faster and safer: a randomized controlled trial. Proc Natl Acad Sci U S A. 2008; 105 (46): 17908–12. DOI: https://doi.org/10.1073/pnas.0803725105
21. Senti G., Crameri R., Kuster D., Johansen P., Martinez-Gomez J.M., Graf N., Steiner M., Hothorn L.A., Grönlund H., Tivig C., Zaleska A., Soyer O., van Hage M., Akdis C.A., Akdis M., Rose H., Kündig T.M. Intralymphatic immunotherapy for cat allergy induces tolerance after only 3 injections. J Allergy Clin Immunol. 2012; 129 (5): 1290–6. DOI: https://doi.org/10.1016/j.jaci.2012.02.026
22. Veneziani I., Landolina N., Ricci B., Rossi O., Moretta L., Maggi E. How the Immune System Responds to Allergy Immunotherapy. Biomedicines. 2022; 10 (11): 2825. DOI: https://doi.org/10.3390/biomedicines10112825
23. Xiong L., Lin J., Luo Y., Chen W., Dai J. The Efficacy and Safety of Epicutaneous Immunotherapy for Allergic Diseases: A Systematic Review and Meta-Analysis. Int Arch Allergy Immunol. 2020; 181 (3): 170–82. DOI: https://doi.org/10.1159/000504366
24. Pavón-Romero G.F., Parra-Vargas M.I., Ramírez-Jiménez F., Melgoza-Ruiz E., Serrano-Pérez N.H., Teran L.M. Allergen Immunotherapy: Current and Future Trends. Cells. 2022; 11 (2): 212. DOI: https://doi.org/10.3390/cells11020212
25. Satitsuksanoa P., Angelina A., Palomares O., Akdis M. Mechanisms in AIT: Insights 2021. Allergol Select. 2022; 6: 259–66. DOI: https://doi.org/10.5414/ALX02300E
26. Marshall J.D., Abtahi S., Eiden J.J., Tuck S., Milley R., Haycock F., Reid M.J., Kagey-Sobotka A., Creticos P.S., Lichtenstein L.M., Van Nest G. Immunostimulatory sequence DNA linked to the Amb a 1 allergen promotes T(H)1 cytokine expression while downregulating T(H)2 cytokine expression in PBMCs from human patients with ragweed allergy. J Allergy Clin Immunol. 2001; 108 (2): 191–7. DOI: https://doi.org/10.1067/mai.2001.116984
27. Moseman E.A., Liang X., Dawson A.J., Panoskaltsis-Mortari A., Krieg A.M., Liu Y.J., Blazar B.R., Chen W. Human plasmacytoid dendritic cells activated by CpG oligodeoxynucleotides induce the generation of CD4+CD25+ regulatory T cells. J Immunol. 2004; 173 (7): 4433–42. DOI: https://doi.org/10.049/jimmunol.173.7.4433
28. Creticos P.S., Schroeder J.T., Hamilton R.G., Balcer-Whaley S.L., Khattignavong A.P., Lindblad R., Li H., Coffman R., Seyfert V., Eiden J.J., Broide D.; Immune Tolerance Network Group. Immunotherapy with a ragweed-toll-like receptor 9 agonist vaccine for allergic rhinitis. N Engl J Med. 2006; 355 (14): 1445–55. DOI: https://doi.org/10.1056/NEJMoa052916
29. Puggioni F., Durham S.R., Francis J.N. Monophosphoryl lipid A (MPL) promotes allergen-induced immune deviation in favour of Th1 responses. Allergy. 2005; 60 (5): 678–84. DOI: https://doi.org/10.1111/j.1398-9995.2005.00762.x
30. Drachenberg K.J., Wheeler A.W., Stuebner P., Horak F. A well-tolerated grass pollen-specific allergy vaccine containing a novel adjuvant, monophosphoryl lipid A, reduces allergic symptoms after only four preseasonal injections. Allergy. 2001; 56 (6): 498–505. DOI: https://doi.org/10.1034/j.1398-9995.2001.056006498.x
31. Rosewich M., Girod K., Zielen S., Schubert R., Schulze J. Induction of Bronchial Tolerance After 1 Cycle of Monophosphoryl-A-Adjuvanted Specific Immunotherapy in Children with Grass Pollen Allergies. Allergy Asthma Immunol Res. 2016; 8 (3): 257–63. DOI: https://doi.org/10.4168/aair.2016.8.3.257
32. Kurbacheva O.M., Pavlova K.S. Allergen-specific immunotherapy: modern possibilities. Asthma and allergy. 2015; (3): 16–20. eLIBRARY ID: 25797349. (in Russian)
33. Pfaar O., Ankermann T., Augustin M., Bubel P., Böing S., Brehler R., Eng P.A, Fischer P.J., Gerstlauer M., Hamelmann E., Jakob T., Kleine-Tebbe J., Kopp M.V., Lau S., Mülleneisen N., Müller C., Nemat K., Pfützner W., Saloga J., Strömer K., Schmid-Grendelmeier P., Schuster A., Sturm GJ., Taube C., Szépfalusi Z., Vogelberg C., Wagenmann M., Wehrmann W., Werfel T., Wöhrl S., Worm M., Wedi B; Commenting participation and process support:; Kaul S., Mahler V., Schwalfenberg A. Guideline on allergen immunotherapy in IgE-mediated allergic diseases: S2K Guideline of the German Society of Allergology and Clinical Immunology (DGAKI), Society of Pediatric Allergology and Environmental Medicine (GPA), Medical Association of German Allergologists (AeDA), Austrian Society of Allergology and Immunology (ÖGAI), Swiss Society for Allergology and Immunology (SSAI), German Dermatological Society (DDG), German Society of Oto-Rhino-Laryngology, Head and Neck Surgery (DGHNO-KHC), German Society of Pediatrics and Adolescent Medicine (DGKJ), Society of Pediatric Pulmonology (GPP), German Respiratory Society (DGP), German Professional Association of Otolaryngologists (BVHNO), German Association of Paediatric and Adolescent Care Specialists (BVKJ), Federal Association of Pneumologists, Sleep and Respiratory Physicians (BdP), Professional Association of German Dermatologists (BVDD). Allergol Select. 2022; 6: 167–232. DOI: https://doi.org/10.5414/ALX02331E
34. Mothes N., Heinzkill M., Drachenberg K.J., Sperr W.R., Krauth M.T., Majlesi Y., Semper H., Valent P., Niederberger V., Kraft D., Valenta R. Allergen-specific immunotherapy with a monophosphoryl lipid A-adjuvanted vaccine: reduced seasonally boosted immunoglobulin E production and inhibition of basophil histamine release by therapy-induced blocking antibodies. Clin Exp Allergy. 2003; 33 (9): 1198–208. DOI: https://doi.org/10.1046/j.1365-2222.2003.01699.x
35. Chen K.W., Zieglmayer P., Zieglmayer R., Lemell P., Horak F., Bunu C.P., Valenta R., Vrtala S. Selection of house dust mite-allergic patients by molecular diagnosis may enhance success of specific immunotherapy. J Allergy Clin Immunol. 2019; 143 (3): 1248–52.e12. DOI: https://doi.org/10.1016/j.jaci.2018.10.048
36. Movérare R., Elfman L., Vesterinen E., Metso T., Haahtela T. Development of new IgE specificities to allergenic components in birch pollen extract during specific immunotherapy studied with immunoblotting and Pharmacia CAP System. Allergy. 2002; 57 (5): 423–30. DOI: https://doi.org/10.1034/j.1398-9995.2002.13248.x
37. Pauli G., Larsen T.H., Rak S., Horak F., Pastorello E., Valenta R., Purohit A., Arvidsson M., Kavina A., Schroeder J.W., Mothes N., Spitzauer S., Montagut A., Galvain S., Melac M., André C., Poulsen L.K., Malling H.J. Efficacy of recombinant birch pollen vaccine for the treatment of birch-allergic rhinoconjunctivitis. J Allergy Clin Immunol. 2008; 122 (5): 951–60. DOI: https://doi.org/10.1016/j.jaci.2008.09.017
38. Campana R., Marth K., Zieglmayer P., Weber M., Lupinek C., Zhernov Y., Elisyutina O., Khaitov M., Rigler E., Westritschnig K., Berger U., Wolkersdorfer M., Horak F. Jr., Horak F., Valenta R. Vaccination of nonallergic individuals with recombinant hypoallergenic fragments of birch pollen allergen Bet v 1: Safety, effects, and mechanisms. J Allergy Clin Immunol. 2019; 143 (3): 1258–61. DOI: https://doi.org/10.1016/j.jaci.2018.11.011
39. Tulaeva I., Kratzer B., Campana R., Curin M., van Hage M., Karsonova A., Riabova K., Karaulov A., Khaitov M., Pickl W.F., Valenta R. Preventive Allergen-Specific Vaccination Against Allergy: Mission Possible? Front Immunol. 2020; 11: 1368. DOI: https://doi.org/10.3389/fimmu.2020.01368
40. Larché M. T cell epitope-based allergy vaccines. Curr Top Microbiol Immunol. 2011; 352: 107–19. DOI: https://doi.org/10.1007/82_2011_131
41. Kündig T.M., Senti G., Schnetzler G., Wolf C., Prinz Vavricka B.M., Fulurija A., Hennecke F., Sladko K., Jennings G.T., Bachmann MF. Der p 1 peptide on virus-like particles is safe and highly immunogenic in healthy adults. J Allergy Clin Immunol. 2006; 117 (6): 1470–6. DOI: https://doi.org/10.1016/j.jaci.2006.01.040
42. Wang X.Y., Ma T.T., Wang X.Y., Zhuang Y., Wang X.D., Ning H.Y., Shi H.Y., Yu R.L., Yan D., Huang H.D., Bai Y.F., Shan G.L., Zhang B., Song Q.K., Zhang Y.F., Zhang T.J., Jia D.Z., Liu X.L., Kang Z.X., Yan W.J., Yang B.T., Bao X.Z., Sun S.H., Zhang F.F., Yu W.H., Bai C.L., Wei T., Yang T., Ma T.Q., Wu X.B., Liu J.G., Du H., Zhang L., Yan Y., Wang D.Y. Prevalence of pollen-induced allergic rhinitis with high pollen exposure in grasslands of northern China. Allergy. 2018; 73 (6): 1232–43. DOI: https://doi.org/10.1111/all.13388
43. Ma T., Wang X., Zhuang Y., Shi H., Ning H., Lan T., Zhang T., Kang Z., SiQin B., Yang B., Bao X., Yan W., Lei T., Wang D., Shan G., Zhang B., Wang X., Zhang L. Prevalence and risk factors for allergic rhinitis in adults and children living in different grassland regions of Inner Mongolia. Allergy. 2020; 75 (1): 234–39. DOI: https://doi.org/10.1111/all.13941
44. Niederberger V., Marth K., Eckl-Dorna J., Focke-Tejkl M., Weber M., Hemmer W., Berger U., Neubauer A., Stolz F., Henning R., Valenta R. Skin test evaluation of a novel peptide carrier-based vaccine, BM32, in grass pollen-allergic patients. J Allergy Clin Immunol. 2015; 136 (4): 1101–3.e8. DOI: https://doi.org/10.1016/j.jaci.2015.03.034
45. Zieglmayer P., Focke-Tejkl M., Schmutz R., Lemell P., Zieglmayer R., Weber M., Kiss R., Blatt K., Valent P., Stolz F., Huber H., Neubauer A., Knoll A., Horak F., Henning R., Valenta R. Mechanisms, safety and efficacy of a B cell epitope-based vaccine for immunotherapy of grass pollen allergy. EBioMedicine. 2016; 11: 43–57. DOI: https://doi.org/10.1016/j.ebiom.2016.08.022
46. Rauber M.M., Möbs C., Campana R., Henning R., Schulze-Dasbeck M., Greene B., Focke-Tejkl M., Weber M., Valenta R., Pfützner W. Allergen immunotherapy with the hypoallergenic B-cell epitope-based vaccine BM32 modifies IL-10- and IL-5-secreting T cells. Allergy. 2020; 75 (2): 450–43. DOI: https://doi.org/10.1111/all.13996
47. Niederberger V., Neubauer A., Gevaert P., Zidarn M., Worm M., Aberer W., Malling H.J., Pfaar O., Klimek L., Pfützner W., Ring J., Darsow U., Novak N., Gerth van Wijk R., Eckl-Dorna J., Focke-Tejkl M., Weber M., Müller H.H., Klinger J., Stolz F., Breit N., Henning R., Valenta R. Safety and efficacy of immunotherapy with the recombinant B-cell epitope-based grass pollen vaccine BM32. J Allergy Clin Immunol. 2018; 142 (2): 497–509.e9. DOI: https://doi.org/10.1016/j.jaci.2017.09.052
48. Eckl-Dorna J., Weber M., Stanek V., Linhart B., Ristl R., Waltl E.E., Villazala-Merino S., Hummel A., Focke-Tejkl M., Froeschel R., Neubauer A., Henning R., Perkmann T., Valenta R., Niederberger V. Two years of treatment with the recombinant grass pollen allergy vaccine BM32 induces a continuously increasing allergen-specific IgG4 response. EBioMedicine. 2019; 50: 421–32. DOI: https://doi.org/10.1016/j.ebiom.2019.11.006
49. Tulaeva I., Cornelius C., Zieglmayer P., Zieglmayer R., Schmutz R., Lemell P., Weber M., Focke-Tejkl M., Karaulov A., Henning R., Valenta R. Quantification, epitope mapping and genotype cross-reactivity of hepatitis B preS-specific antibodies in subjects vaccinated with different dosage regimens of BM32. EBioMedicine. 2020; 59: 102953. DOI: https://doi.org/10.1016/j.ebiom.2020.102953
50. Khaitov M., Shilovskiy I., Valenta R., Weber M., Korneev A., Tulaeva I., Gattinger P., van Hage M., Hofer G., Konradsen J.R., Keller W., Akinfenwa O., Poroshina A., Ilina N., Fedenko E., Elisyutina O., Litovkina A., Smolnikov E., Nikonova A., Rybalkin S., Aldobaev V., Smirnov V., Shershakova N., Petukhova O., Kudlay D., Shatilov A., Timofeeva A., Campana R., Udin S., Skvortsova V. Recombinant PreS-fusion protein vaccine for birch pollen and apple allergy. Allergy. 2023. Oct 19. DOI: https://doi.org/10.1111/all.15919
51. Shamji M.H., Singh I., Layhadi J.A., Ito C., Karamani A., Kouser L., et al. Passive Prophylactic Administration with a Single Dose of Anti-Fel d 1 Monoclonal Antibodies REGN1908-1909 in Cat Allergen-induced Allergic Rhinitis: A Randomized, Double-Blind, Placebo-controlled Clinical Trial. Am J Respir Crit Care Med. 2021; 23–33. DOI: https://doi.org/10.1164/RCCM.202011-4107OC
52. Heeringa J.J., McKenzie C.I., Varese N., Hew M., Bakx ATCM, Aui P.M., Rolland J.M., O’Hehir R.E., van Zelm M.C. Induction of IgG2 and IgG4 B-cell memory following sublingual immunotherapy for ryegrass pollen allergy. Allergy. 2020; 75 (5): 1121–32. DOI: https://doi.org/10.1111/all.14073
53. Jiménez-Saiz R., Patil S.U. The Multifaceted B Cell Response in Allergen Immunotherapy. Curr Allergy Asthma Rep. 2018; 18 (12): 66. DOI: https://doi.org/10.1007/s11882-018-0819-1
54. Komlósi Z.I., Kovács N., Sokolowska M., van de Veen W., Akdis M., Akdis C.A. Mechanisms of Subcutaneous and Sublingual Aeroallergen Immunotherapy: What Is New? Immunol Allergy Clin North Am. 2020; 40 (1): 1–14. DOI: https://doi.org/10.1016/j.iac.2019.09.009
55. Golebski K., Layhadi JA., Sahiner U., Steveling-Klein E.H., Lenormand M.M., Li R.C.Y., Bal S.M., Heesters B.A., Vilà-Nadal G., Hunewald O., Montamat G., He F.Q., Ollert M., Fedina O., Lao-Araya M., Vijverberg S.J.H., Maitland-van der Zee A.H., van Drunen C.M., Fokkens W.J., Durham S.R., Spits H., Shamji M.H. Induction of IL-10-producing type 2 innate lymphoid cells by allergen immunotherapy is associated with clinical response. Immunity. 2021; 54 (2): 291–307.e7. DOI: https://doi.org/10.1016/j.immuni.2020.12.013
56. Sahiner U.M., Giovannini M., Escribese M.M., Paoletti G., Heffler E., Alvaro Lozano M., Barber D., Canonica G.W., Pfaar O. Mechanisms of Allergen Immunotherapy and Potential Biomarkers for Clinical Evaluation. J Pers Med. 2023; 13 (5): 845. DOI: https://doi.org/10.3390/jpm13050845
57. Shamji M.H., Layhadi J.A., Sharif H., Penagos M., Durham S.R. Immunological Responses and Biomarkers for Allergen-Specific Immunotherapy Against Inhaled Allergens. J Allergy Clin Immunol Pract. 2021; 9 (5): 1769–78. DOI: https://doi.org/10.1016/j.jaip.2021.03.029
58. Satitsuksanoa P., Daanje M., Akdis M., Boyd S.D, van de Veen W. Biology and dynamics of B cells in the context of IgE-mediated food allergy. Allergy. 2021; 76 (6): 1707–17. DOI: https://doi.org/10.1111/all.14684
59. Jansen K., Cevhertas L., Ma S., Satitsuksanoa P., Akdis M., van de Veen W. Regulatory B cells, A to Z. Allergy. 2021; 76 (9): 2699–715. DOI: https://doi.org/10.1111/all.14763
60. Ma S., Satitsuksanoa P., Jansen K., Cevhertas L., van de Veen W., Akdis M. B regulatory cells in allergy. Immunol Rev. 2021; 299 (1): 10–30. DOI: https://doi.org/10.1111/imr.12937
61. Celebi Sözener Z., Mungan D., Cevhertas L., Ogulur I., Akdis M., Akdis C. Tolerance mechanisms in allergen immunotherapy. Curr Opin Allergy Clin Immunol. 2020; 20 (6): 591–601. DOI: https://doi.org/10.1097/ACI.0000000000000693
62. Schmid J.M., Würtzen P.A., Siddhuraj P., Jogdand P., Petersen C.G., Dahl R., Erjefält J.S., Hoffmann H.J. Basophil sensitivity reflects long-term clinical outcome of subcutaneous immunotherapy in grass pollen-allergic patients. Allergy. 2021; 76 (5): 1528–38. DOI: https://doi.org/10.1111/all.14264
63. Kanagaratham C., El Ansari Y.S., Lewis O.L., Oettgen H.C. IgE and IgG Antibodies as Regulators of Mast Cell and Basophil Functions in Food Allergy. Front Immunol. 2020; 11: 603050. DOI: https://doi.org/10.3389/fimmu.2020.603050
64. Valovirta E., Petersen T.H., Piotrowska T., Laursen M.K., Andersen J.S., Sørensen H.F., Klink R.; GAP investigators. Results from the 5-year SQ grass sublingual immunotherapy tablet asthma prevention (GAP) trial in children with grass pollen allergy. J Allergy Clin Immunol. 2018; 141 (2): 529–38.e13. DOI: https://doi.org/10.1016/j.jaci.2017.06.014
65. Alvaro-Lozano M., Akdis C.A., Akdis M., Alviani C., Angier E., Arasi S., Arzt-Gradwohl L., Barber D., Bazire R., Cavkaytar O., Comberiati P., Dramburg S., Durham S.R., Eifan A.O., Forchert L., Halken S., Kirtland M., Kucuksezer UC., Layhadi JA., Matricardi P.M., Muraro A., Ozdemir C., Pajno G.B., Pfaar O., Potapova E., Riggioni C., Roberts G., Rodríguez Del Río P., Shamji M.H., Sturm G.J., Vazquez-Ortiz M. EAACI Allergen Immunotherapy User’s Guide. Pediatr Allergy Immunol. 2020; 31 (Suppl. 25): 1–101. DOI: https://doi.org/10.1111/pai.13189
66. Kortekaas Krohn I., Shikhagaie M.M., Golebski K., Bernink J.H., Breynaert C., Creyns B., Diamant Z., Fokkens W.J., Gevaert P., Hellings P., Hendriks R.W., Klimek L., Mjösberg J., Morita H., Ogg G.S., O’Mahony L., Schwarze J., Seys S.F., Shamji M.H., Bal S.M. Emerging roles of innate lymphoid cells in inflammatory diseases: Clinical implications. Allergy. 2018; 73 (4): 837–50. DOI: https://doi.org/10.1111/all.13340
67. Morita H., Kubo T., Rückert B., Ravindran A., Soyka M.B., Rinaldi A.O., Sugita K., Wawrzyniak M., Wawrzyniak P., Motomura K., Tamari M., Orimo K., Okada N., Arae K., Saito K., Altunbulakli C., Castro-Giner F., Tan G., Neumann A., Sudo K., O’Mahony L., Honda K., Nakae S., Saito H., Mjösberg J., Nilsson G., Matsumoto K., Akdis M., Akdis C.A. Induction of human regulatory innate lymphoid cells from group 2 innate lymphoid cells by retinoic acid. J Allergy Clin Immunol. 2019; 143 (6): 2190–201.e9. DOI: https://doi.org/10.1016/j.jaci.2018.12.1018
68. Wang L.X., Zhang S.X., Wu H.J., Rong X.L., Guo J. M2b macrophage polarization and its roles in diseases. J Leukoc Biol. 2019; 106 (2): 345–58. DOI: https://doi.org/10.1002/JLB.3RU1018-378RR
69. Lou H., Huang Y., Chen H., Wang Y., Zhang L., Wang C. M2 macrophages correlated with symptom severity and promote type 2 inflammation in allergic rhinitis. Allergy. 2019; 74 (11): 2255–57. DOI: https://doi.org/10.1111/all.13852
70. Chung S., Kim J.Y., Song M.A., Park G.Y., Lee Y.G., Karpurapu M., Englert J.A., Ballinger M.N., Pabla N., Chung H.Y., Christman J.W. FoxO1 is a critical regulator of M2-like macrophage activation in allergic asthma. Allergy. 2019; 74 (3): 535–48. DOI: https://doi.org/10.1111/all.13626
71. Bianchini R., Roth-Walter F., Ohradanova-Repic A., Flicker S., Hufnagl K., Fischer M.B., Stockinger H., Jensen-Jarolim E. IgG4 drives M2a macrophages to a regulatory M2b-like phenotype: potential implication in immune tolerance. Allergy. 2019; 74 (3): 483–94. DOI: https://doi.org/10.1111/all.13635